I normally don’t share anything from lie hub but
Post# of 148166
(Total Views: 742)
Posted On: 01/28/2022 2:06:24 AM
I normally don’t share anything from lie hub but I like this post.
From Jimmy
“It takes titanium cohones to be successful in pre-revenue biotech battleground disruptive companies. Also experience of seeing it finally playout positive on other stocks. Been there done that. The "Market" is a liar or blind it these stocks. Five Prime and Anavex Life Sciences are recent examples as well as Arrowhead 18 months earlier. All supremely bashed by naysayers. CytoDyn is bigger than all in potential. Adam F. called Arrowhead CEO the worst in biotech in the next 18 months it went from $200 mil market cap to $7 billion with no approvals. ARWR was a big winner as well as the "Fire Dr Missling" super bashed AVXL. AVXL rose 25x in 18 months just recently. BTW AVXL rose up from OTC and rose 5x within weeks of up listing
Five Prime was beaten down from $30 plus over 3 years to below $5 and rose to $38 in under 5 months.
These things take time. It is a hard road termed the "Regulatory Desert" where water ( funding) is scarce and disruptive companies are beset on all sides by naysayers, heartless and jealous enemies.
The Anavex drug is still unproven but it has finally been "Market Recognized ".
Resulting in a proper market cap. AWRW spent more than 20 years in the regulatory desert and might be a future Regeneron and holds a market cap reflecting "market acceptance" market cap with important BP partnerships. Buying CYDY now is like having the foresight to buy AVXL at $1.26 or ARWR at $2.60.
With Nader gone things could move quickly on the partnership front.
When I bought ARWR and AVXL in the $200 market cap range I had a current "fair market cap" valuation of $1-3 billion on "market recognition". The goal is not Regulatory Aporoval it is "Market Recognition".
The market recognition value, I place on CYDY is $3-7 billion just as it sits now on potential alone but will require an up list.
For an example of an Arrowhead type stock than spent more than 20 years in the Regulatory Desert and completely and consistently bashed see NWBO.
As a long you have to endure a London type blitz and emerge fighting accumulating all the while.
One must be willing to hold 5 years or more during the down turns and be confident enough in your own DD not to sell to soon in the 18 months of the "worm turn" of the "market acceptance " rapid upward valuation curve.
Know What You Hold!”
From Jimmy
“It takes titanium cohones to be successful in pre-revenue biotech battleground disruptive companies. Also experience of seeing it finally playout positive on other stocks. Been there done that. The "Market" is a liar or blind it these stocks. Five Prime and Anavex Life Sciences are recent examples as well as Arrowhead 18 months earlier. All supremely bashed by naysayers. CytoDyn is bigger than all in potential. Adam F. called Arrowhead CEO the worst in biotech in the next 18 months it went from $200 mil market cap to $7 billion with no approvals. ARWR was a big winner as well as the "Fire Dr Missling" super bashed AVXL. AVXL rose 25x in 18 months just recently. BTW AVXL rose up from OTC and rose 5x within weeks of up listing
Five Prime was beaten down from $30 plus over 3 years to below $5 and rose to $38 in under 5 months.
These things take time. It is a hard road termed the "Regulatory Desert" where water ( funding) is scarce and disruptive companies are beset on all sides by naysayers, heartless and jealous enemies.
The Anavex drug is still unproven but it has finally been "Market Recognized ".
Resulting in a proper market cap. AWRW spent more than 20 years in the regulatory desert and might be a future Regeneron and holds a market cap reflecting "market acceptance" market cap with important BP partnerships. Buying CYDY now is like having the foresight to buy AVXL at $1.26 or ARWR at $2.60.
With Nader gone things could move quickly on the partnership front.
When I bought ARWR and AVXL in the $200 market cap range I had a current "fair market cap" valuation of $1-3 billion on "market recognition". The goal is not Regulatory Aporoval it is "Market Recognition".
The market recognition value, I place on CYDY is $3-7 billion just as it sits now on potential alone but will require an up list.
For an example of an Arrowhead type stock than spent more than 20 years in the Regulatory Desert and completely and consistently bashed see NWBO.
As a long you have to endure a London type blitz and emerge fighting accumulating all the while.
One must be willing to hold 5 years or more during the down turns and be confident enough in your own DD not to sell to soon in the 18 months of the "worm turn" of the "market acceptance " rapid upward valuation curve.
Know What You Hold!”
(12)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼